Sign up Australia
Proactive Investors - Run By Investors For Investors

Midatech making “significant progress” with two of its key clinical programmes

Early data from the first-in-human study of Midatech’s acromegaly and carcinoid cancer drug, MTD201 is due within the next few months, while its, MTX110 brain cancer treatment continues to “progress well”
cancer cell
Sales grew once again in the first half of the year

Drug developer Midatech Pharma Plc (LON:MTPH) has praised the “significant progress” it made with two of its key clinical programmes in the first half of the year.

The AIM-quoted firm remains on track to announce the results of the initial phase of the ongoing first-in-human study of its MTD201 drug towards the end of Q3 or start of Q4 this year.

MTD201 is being developed as a treatment for a hormonal disorder called acromegaly as well as for carcinoid cancer.

READ: Midatech primed and funded for success

Its other key clinical programme, called MTX110, a potential treatment for a rare type of brain tumour found in children, continues to “progress well”.

Midatech added that preparation work to take its MTD119 liver cancer drug into the clinic is currently underway.

Away from the lab, the firm is on course to meet full-year market expectations after a solid first-half performance.

For the six months to June 30 2018, Midatech is guiding for revenue of £5.8mln, a 16% increase from the £5.0mln it posted for the same period last year.

Sales for the second half of 2017 represented 56% of full-year gross product sales, and Midatech anticipates a similar split in 2018.

As it has said before, the company continues to look at ways to meet its cash flow needs, including non-dilutive financing.

“I am pleased to report a strong trading update for the first half of the year, with continued sales growth in our US business and significant progress made in our key clinical programmes, MTD201 and MTX110,” said chief executive Craig Cook.

“There is renewed momentum throughout the group as we progress towards the key value inflection points for our clinical pipeline over the next eighteen months, and we remain focused on bringing our innovative and potentially life-changing therapies to market in areas of significant unmet need.”

View full MTPH profile View Profile

Midatech Pharma Plc Timeline

Related Articles

The biotech was founded by an investment group led by scientists and driven by a no-nonsense CEO whose stake is more than just business as usual
scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use